CJC-1295 No DAC vs DAC: Research Context and Analytical Considerations

Research Library › GHRH Analogue Comparison

CJC-1295 No DAC versus DAC research begins with a naming and identity distinction. Published CJC-1295 literature primarily describes a long-acting, albumin-binding GHRH analogue; materials labeled “No DAC” require separate identity documentation and should not be treated as the same analyte with a shorter schedule.

Start with the analyte name

CJC-1295 was described in the literature as a growth hormone-releasing hormone analogue engineered with a Drug Affinity Complex. The modification enables covalent interaction with circulating albumin and changes the material’s persistence profile. “CJC-1295 No DAC” is a commercial naming convention used for a non-DAC GHRH analogue. Because the presence or absence of the modification changes molecular identity, the two labels should not be interpreted as interchangeable versions of one verified analyte.

DAC and albumin-binding research

Primary studies of CJC-1295 with DAC examined albumin association, prolonged exposure, growth hormone-releasing hormone receptor activity, and downstream signaling measurements. That evidence belongs to the DAC-modified material used in those experiments. It should not be transferred automatically to a non-DAC research material based on a shared base name.

No DAC research framework

CJC-1295 No DAC is positioned for shorter-duration GHRH-receptor research in which transient exposure and time-resolved sampling are relevant. A defensible study should identify the exact sequence, modification state, expected molecular mass, and lot-specific analytical evidence rather than relying on “No DAC” alone as a chemical definition.

• Confirm whether the tested material contains an albumin-binding modification.
• Record the complete sequence or structural description supplied for the lot.
• Align sampling windows with the exposure profile being investigated.
• Do not use DAC-specific literature as direct identity evidence for a non-DAC material.

Designing a DAC versus No DAC comparison

A comparative design should treat CJC-1295 DAC and No DAC as separate analytes. Use matched vehicle conditions, report the same analytical endpoints, and select time points capable of resolving both early and sustained responses. A single late measurement can obscure a shorter signal, while a single early measurement may not describe a prolonged exposure profile.

If Ipamorelin is included, its ghrelin-receptor pathway introduces another experimental variable. The GH Release Bundle organizes CJC-1295 No DAC and Ipamorelin as separate documented materials; component controls remain necessary when the purpose is to attribute an observed response.

Analytical identity and purity

Chromatographic purity does not establish the full identity of a GHRH analogue. Mass spectrometry can support an expected molecular signal, while chromatography can characterize purity and related species. Sequence confirmation, modification state, counterion information, reference standards, and method suitability may require additional evidence depending on the research question.

1. Match the product label, lot number, and stated strength to the report.
2. Confirm whether the report identifies DAC or No DAC material.
3. Compare the measured molecular signal with the expected analyte.
4. Review chromatographic purity and any reported secondary peaks.
5. Preserve preparation, handling, and storage history in the study record.

Evidence boundary

Published CJC-1295 studies include animal and controlled human research involving specific DAC-modified preparations. Those findings do not establish the identity, purity, activity, safety, or efficacy of another lot. Likewise, a pathway-level result does not support therapeutic or performance claims. Conclusions should remain attached to the analyte, formulation, model, controls, sampling schedule, and endpoints directly examined.

Reporting the material

A reproducible report should state DAC status, sequence or structural description, supplier, lot number, labeled strength, analytical methods, preparation conditions, storage history, model, controls, time points, and measured endpoints. When comparing the two materials, describe them as separate analytes and avoid shortening both names to “CJC-1295” after the methods section.

For a receptor-pathway comparison with a growth-hormone secretagogue, review CJC-1295 No DAC vs Ipamorelin.

References

1. Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analogue. Endocrinology. 2005.
2. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006.
3. Ionescu M, Frohman LA. Pulsatile growth hormone secretion during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006.
4. Memdouh S, et al. Advances in the detection of growth hormone-releasing hormone synthetic analogues. Drug Testing and Analysis. 2022.

Return to the Research Library